Upload
others
View
0
Download
0
Embed Size (px)
Citation preview
1 Dr S. Kopp, TSN/WHO
WHO' normative functions in the field of pharmaceuticals
What can WHO offer ?
Dr Sabine Kopp
Group Lead, Medicines Quality Assurance
Technologies Standards and Norms
Regulation of Medicines and Other Health Technologies
Essential Medicines and Health Products
World Health Organization
2 Dr S. Kopp, TSN/WHO
World Health Assembly – Constitution, basic legal texts and Resolutions
3 Dr S. Kopp, TSN/WHO
WHO Expert Committees rules and procedures WHO Basic Documents
Constitution of WHO Expert Committees:
chapter V, article 18; chapter VIII, articles 38-40 For normative function - pharmaceuticals:
Chapter 2, article 2 (u): " to develop, establish and promote international standards with respect to food, biological, pharmaceutical and similar products;"
Regulations for Expert Advisory Panels and Committees, including, Annex – Rules of Procedure for Expert Committees
4 Dr S. Kopp, TSN/WHO
WHO Governing bodies – DG Report on WHO Expert Committee on Specifications for Pharmaceutical Preparations meetings
5 Dr S. Kopp, TSN/WHO
What is a WHO Expert Committee?
Official Advisory Body to Director-General of WHO
Established by World Health Assembly or Executive Board
Governed through rules and procedures
Participation in Expert Committee (EC) meetings:
Members ("Experts") selected from WHO Expert Advisory Panels
Technical advisers
Observers: - international organizations, - NGOs, - professional associations…
6 Dr S. Kopp, TSN/WHO
Expert Committee on Specifications for Pharmaceutical Preparations (ECSPP)
Covers today WHO’s guidance for medicines quality assurance:
Development
Production
Quality Control
Quality related regulatory guidelines
Inspection
Distribution and supply
lifecycle of medicines
from development to delivery to the patient
7 Dr S. Kopp, TSN/WHO
ECSPP adopts WHO GXPs, guidance texts and guidelines in medicines quality assurance
Total - without Ph.Int. - of :
More than 75 CURRENT official WHO
guidance texts and guidelines for
medicines quality assurance, including
8 (6 updates, 2 new published in 2014)
9 (6 updates, 3 new published in 2015)
8 Dr S. Kopp, TSN/WHO
http://www.who.int/medicines/areas/quality_safety/quality_assurance/en/
9 Dr S. Kopp, TSN/WHO
5th Edition of Ph.Int. in press! http://apps.who.int/phint/en/
Monographs
on pharmaceutical substances
on specific dosage forms
general on dosage forms
texts on methods of analysis
monographs on radiopharmaceuticals
and physical standards
International Chemical Reference Substances (ICRS)
10 Dr S. Kopp, TSN/WHO
WHO Partners in the Expert Committee on Specifications for Pharmaceutical Preparations
National and regional authorities
International organizations (UNAIDS, UNFPA, UNICEF,
World Bank, WIPO, WTO, WCO, etc)
International professional and other associations,
NGOs (including consumer associations, MSF,
industry: IFPMA-IGPA- WSMI, FIP, WMA, etc)
Members of the WHO Expert Advisory Panel on the
International Pharmacopoeia and Pharmaceutical
Preparations
11 Dr S. Kopp, TSN/WHO
How to become a "WHO Expert"?
Official nomination process
Upon proposal to WHO in consultation with:
Member State/national government (citizenship)+
WHO Regional Office (in accordance with
Member State) +
WHO Headquarters
First period of 4 years
Possibility to renew
12 Dr S. Kopp, TSN/WHO
WHO Partners in the Expert Committee on Specifications for Pharmaceutical Preparations
Specialists from all quality assurance related areas,
including regulatory, university, industry
WHO Collaborating Centres (official nomination
process) – usually national quality control labs
Pharmacopoeia Commissions and Secretariats,
national institutions and institutes ..
Regional and interregional groups (ICH, ASEAN, etc)
13 Dr S. Kopp, TSN/WHO
Outcome of the WHO Expert Committee?
Report of the WHO Expert Committee:
- Summarizes discussion
- Gives recommendations to WHO + Member States
- Includes newly adopted guidelines;
- Is presented to WHO Governing Bodies for final comments, endorsement and implementation by Member States
constitutes WHO technical guidance
14 Dr S. Kopp, TSN/WHO
When does the ECSPP start development of a guideline/guidance/GXP?
Based on recommendations by :
World Health Assembly resolutions (e.g. WHA 20.34, GMP - Good manufacturing practices)
Executive Board resolutions (e.g. EB37.R9 delegating certain functions of INN Programme to DG based on advice from Experts)
International Conference of Drug Regulatory Authorities (e.g. 10th +11th ICDRA – FDC guidelines + Certification Scheme for pharmaceutical starting materials moving into international commerce)
Other WHO programmes and clusters (e.g. necessity for quality control specifications for specific medicines of major public health interest)
Expert Committee (e.g. revision of general methods included in The International Pharmacopoeia)
15 Dr S. Kopp, TSN/WHO
How does the WHO Expert Committee consultation process work?
Step 1. Preliminary consultation and drafting
Step 2. Draft guidelines
Step 3. Circulation for comments
Step 4. Revision process
.......... (back to step 2 and 3 as often as needed)
16 Dr S. Kopp, TSN/WHO
Additional steps for developments of specifications
To cover "practical" steps, such as:
Provision of samples
Laboratory studies and scientific research for suitability of
test specifications
For details full process adopted by the ECSPP
http://www.who.int/medicines/publications/pharmacopoeia/An
nex1-TRS992.pdf?ua=1
17 Dr S. Kopp, TSN/WHO
How does the WHO Expert Committee consultation process work? (2)
WHO Expert Committee (EC) meeting if guideline adopted, published in EC report as Annex
If specification adopted, published in The International
Pharmacopoeia
-> if not back to steps 2-4 (as on previous slide)
DG report to WHO Governing bodies
Recommendation to Member States for
implementation
18 Dr S. Kopp, TSN/WHO
http://www.who.int/medicines/areas/quality_safety/quality_assurance/en/
19 Dr S. Kopp, TSN/WHO
49th WHO Expert Committee on Specifications for Pharmaceutical Preparations (13-17 October 2014)
Adopted:
Annex 1. Procedure of the development of monographs
for inclusion in The International Pharmacopoeia
(revision);
Annex 2. Updating mechanism for the section on
radiopharmaceuticals in The International
Pharmacopoeia (revision);
Annex 3. Supplementary guidelines on good
manufacturing practices: validation; Appendix 7: non-
sterile process validation (revision);
20 Dr S. Kopp, TSN/WHO
49th WHO Expert Committee on Specifications for Pharmaceutical Preparations (13-17 October 2014)
Adopted:
Annex 4. General guidance for inspectors on “hold-
time” studies (new);
Annex 6. Recommendations for quality requirements
when plant-derived artemisinin is used as a starting
material in the production of antimalarial active
pharmaceutical ingredients (revision);
Annex 7. Guidelines on registration requirements to
establish interchangeability (revision);
21 Dr S. Kopp, TSN/WHO
49th WHO Expert Committee on Specifications for Pharmaceutical Preparations (13-17 October 2014)
Adopted:
Annex 8. Guidance on the selection of comparator
pharmaceutical products for equivalence assessment
of interchangeable multisource (generic) products
(revision);
Annex 9: Good review practices guidelines for
regulatory authorities (new).
22 Dr S. Kopp, TSN/WHO
49th WHO Expert Committee on Specifications for Pharmaceutical Preparations (13-17 October 2014)
Adopted:
16 technical supplements to the WHO model guidance
for the storage and transport of time- and temperature-
sensitive pharmaceutical products were adopted
for publication in a format which is appropriate for
the large volume of this guidance (Annex 5).
23 Dr S. Kopp, TSN/WHO
49th WHO Expert Committee on Specifications for Pharmaceutical Preparations (13-17 October 2014)
Adopted for inclusion in The International
Pharmacopoeia:
For maternal, newborn, child and adolescent health
medicines:
Dexamethasone sodium phosphate (revision)
Dexamethasone phosphate injection
For antiviral medicines, including antiretrovirals:
Atazanavir sulfate
Atazanavir capsules
24 Dr S. Kopp, TSN/WHO
49th WHO Expert Committee on Specifications for Pharmaceutical Preparations (13-17 October 2014)
For anti-tuberculosis medicines:
Kanamycin for injection (revision)
For medicines to treat tropical diseases:
Albendazole chewable tablets (revision)
Levamisole hydrochloride (revision)
Pyrantel embonate (revision)
Pyrantel chewable tablets (revision)
Pyrantel tablets (revision)
25 Dr S. Kopp, TSN/WHO
49th WHO Expert Committee on Specifications for Pharmaceutical Preparations (13-17 October 2014)
For other anti-infective medicines:
Fluconazole capsules
Fluconazole injection
For medicines for anaesthesia, pain and palliative care:
Dextromethorphan hydrobromide
General monographs for dosage forms:
Rectal preparations (revision of the general monograph
on suppositories)
26 Dr S. Kopp, TSN/WHO
49th WHO Expert Committee on Specifications for Pharmaceutical Preparations (13-17 October 2014)
Analytical methods:
Disintegration test for suppositories and rectal
capsules (revision of the chapter titled Disintegration
test for suppositories)
Disintegration test for tablets and capsules (revision)
Following the implementation of the revised general
monograph on parenteral preparations the Committee
adopted the proposed endotoxin limits for 11 parenteral
dosage form monographs lacking such specification,
together with related updates to relevant monographs.
27 Dr S. Kopp, TSN/WHO
49th WHO Expert Committee on Specifications for Pharmaceutical Preparations (13-17 October 2014)
The Committee also adopted
12 newly characterized International Chemical
References Substances (ICRS)
workplan for new monographs to be included in The
International Pharmacopoeia
28 Dr S. Kopp, TSN/WHO
WHO Governing bodies, EB May 2015
29 Dr S. Kopp, TSN/WHO
30 Dr S. Kopp, TSN/WHO
Topics of 50th WHO Expert Committee on Specifications for Pharmaceutical Preparations (12-16 October 2015)
Good pharmacopoeial practices (GPhP) - subject to
concurrence by the world pharmacopoeias on the final
edited text
FIP-WHO technical guidelines: points to consider in the
provision by health-care professionals of children-
specific preparations that are not available as
authorized products
Guidance on GMP: inspection report + Model certificate
Good Trade and Distribution Practices
31 Dr S. Kopp, TSN/WHO
Topics of 50th WHO Expert Committee on Specifications for Pharmaceutical Preparations (12-16 October 2015)
WHO Certification scheme on the quality of
pharmaceutical products moving in international
commerce – (Q & A)
Guidelines on the conduct of surveys of the quality of
medicines
Guidance for organizations performing in vivo
bioequivalence studies
WHO general guidance on variations to multisource
pharmaceutical products
Guidance on good data and record management practices
32 Dr S. Kopp, TSN/WHO
Topics of 50th WHO Expert Committee on Specifications for Pharmaceutical Preparations (12-16 October 2015)
Collaborative procedure between the World Health
Organization (WHO) prequalification team medicines
and national medicines regulatory authorities in the
assessment and accelerated national registration of
WHO-prequalified pharmaceutical products and
vaccines
Good Manufacturing Practices (GMP) for biological
products, adopted by the Expert Committee on
Biological Standardization held concurrently
33 Dr S. Kopp, TSN/WHO
Specifications for inclusion in the PhInt
For maternal, newborn, child and adolescent health medicines:
Estradiol cypionate
Levonorgestrel (revision)
Magnesium sulfate (confirmed)
Magnesium sulfate injection (confirmed)
Misoprostol
Misoprostol dispersion
Misoprostol tablets
Norethisterone (revision)
Norethisterone tablets
34 Dr S. Kopp, TSN/WHO
Specifications for inclusion in the PhInt
Artemether injection (revision)
For anti-tuberculosis medicines:
Cycloserine (revision)
Cycloserine capsules (revision)
For medicines for chronic diseases and for mental health:
Carbamazepine
Carbamazepine tablets
Carbamazepine chewable tablets
Carbamazepine oral suspension
35 Dr S. Kopp, TSN/WHO
Specifications for inclusion in the PhInt
For other anti-infective medicines:
Clindamycin hydrochloride
Clindamycin hydrochloride capsules
Flucytosine
Flucytosine infusion
For other medicines:
Dextromethorphan hydrobromide
Dextromethorphan oral solution
36 Dr S. Kopp, TSN/WHO
Specifications for inclusion in the PhInt
-> For the Supplementary section
Levomethorphan limit tests for dextromethorphan-containing
finished products
Chapter on reference substances and reference spectra
-> Workplan for new monographs to be included in PhInt
International Chemical Reference Substances (ICRS)
The Committee endorsed release of 9 ICRS newly
characterized by the custodian centre, the European
Directorate for the Quality of Medicines and HealthCare
(EDQM) and released by the ICRS Board
37 Dr S. Kopp, TSN/WHO
Efforts towards pharmacopoeial convergence facilitated by WHO
DRAFT Good Pharmacopoeial Practices (GPhP) and beyond
5th INTERNATIONAL MEETING OF WORLD PHARMACOPOEIAS co-hosted
by USP 20-22 April 2015, Rockville, USA
6th INTERNATIONAL MEETING OF WORLD PHARMACOPOEIAS – co-
hosted by SFDA/ChPC, Su Zhou, China – 21-23 September 2015
Next meeting: 7th International Meeting of World Pharmacopoeias – co-
hosted by MHLW/PMDA/JP, Japan - 13-15 September 2016
38 Dr S. Kopp, TSN/WHO
Capacity building of national quality control laboratories facilitated by WHO
External quality assurance assessment
scheme for pharmaceutical QC labs (EQAAS)
Phase 6 in 2015 with two tests in one mailing
User-fee based at preferential fees far below cost for
participants from lower- and middle-income countries
39 Dr S. Kopp, TSN/WHO
Examples of recent "success stories"
MODEL QUALITY ASSURANCE SYSTEM FOR
PROCUREMENT AGENCIES (MQAS) recommended by ECSPP
– and adopted as Interagency guideline + implemented by:
UNICEF
UNDP
UNFPA
World Bank
WHO
Plus others such as MSF
40 Dr S. Kopp, TSN/WHO
Importance of international convergence
WHO guidelines and good practices translated into
Chinese, French, Russian, Spanish and
requested in other languages
Requests for permission to translate WHO
quality assurance working documents into
other languages, e.g. Chinese
41 Dr S. Kopp, TSN/WHO
谢谢 شكرا
Thank You! Merci beaucoup!
Спасибо
¡muchas gracias!